Proje Geliştirme ve
Koordinasyon Birimi

2015-10-13 Israel: Understanding the Mechanism of and Developing New Diagnosis and Treatments for Idiopathic Pulmonary Fibrosis (IPF)


 
 Understanding the Mechanism of and Developing New Diagnosis and Treatments for Idiopathic Pulmonary Fibrosis (IPF)

Description of the project offered: 
Idiopathic Pulmonary fibrosis (IPF) is an aggressive, progressive fatal lung disease, of unknown origin, characterized by progressive loss in lung function. In IPF the alveoli and the lung tissue are damaged, becoming thick and scarred, leading to severe breathing difficulties and a compromised oxygen transfer between the lungs and the bloodstream. Leading to shortness of breath that gradually worsens, with respiratory failure being the main cause of death. 
There is no cure for pulmonary fibrosis and only a few treatment options are available. It is estimated that almost 130,000 individuals in the United States and 5 million worldwide suffer from the disease. Pulmonary fibrosis has a particularly poor prognosis and around two-thirds of the patients die within five years after being diagnosed.

IPF research have reported a number of different histopathological characteristics, including alveolar cell hyperplasia, an excess of myofibroblast foci, and aberrant remodeling, and pointed to the involvements of different set of proteins found to be involved in the evolution of the disease, such as the IL4, IL13, Uridine inhibition of collagen and TGF-β production , P13K-AKT pathway, SCGB3A2, MAPKAP kinase 2 (MK2), galectin-3 inhibitor. And have already lead to several successful clinical trials, and two new drugs (Ofev and Esbriet) have received FDA approval and shown to slow down IPF progression, although not curing it. 

The different reported molecular patterns, may suggest a different causes, disease’s progression stage, or a common IPF mechanism that integrated them to a specific molecular network structure and dynamic, that is currently poorly understood, and rarely address in the literature. 

Thus, our goal is to identify the molecular network and its dynamic process, underlining the changes within the IPF lung. We believe that this will lead to the understanding of IPF pathogenesis and setup the basis for intervening in the course of the disease, to block it, are reverse its effects. We also expect that the developed research approach and tools, to be applicable for the understanding of other lung diseases.

Aims and Challenges: 
1. To improve the early diagnosis of idiopathic pulmonary fibrosis (IPF).
2. To offer new insights into the disease and understanding of the mechanisms of IPF
3. To offer new directions for the developments of therapeutic interventions.
4. Exploring the molecular networks underlie the histological of IPF.
5. Identifie patterns of IPF in : mRNA, microRNA expression, alterations in DNA methylation, lung tissue characteristics at different IPF stages. 
6. developing molecular diagnoses for IPF

Specific Aim 
1. Studying cell populations sampled from health and IPF patients. 
2. Studying genomic and transcriptomic profiles of lung sampled from IPF patients. 
3. Animal studies.
4. Early IPF diagnosis, using advance lung imaging systems and analysis methods.
Project proposer:   
Yossi Arzouan (Israel)
Partner role:  Project coordinator 
Partner organisation:  Research
Call for proposal title:  N/A 


Description of the collaboration sought: 
We are looking for partners with knowledge expertise and interest in

We are forming a consortium of multidisciplinary partners from health, academic and industrial sectors, with outstanding knowhow and experience in molecular biology and genomic research of diseases in general and specifically in lung and IPF, as well as clinical, and therapies partners. The consortium should provide the adequate framework required for the achievements of the project's goals of :

1. Identifying the IPF molecular network and its dynamic process.
2. Understanding of IPF pathogenesis 
3. and setup the basis for intervening in the course of the disease, to block, and reverse its effects.

Partners' skills and Expertise needed :

1. Molecular biology with expertise in lung diseases. 
2. Identifying patterns of diseases in : mRNA, microRNA expression, alterations in DNA methylation, 
3. Lung tissue characteristics at different IPF stages. 
4. Animal models of IPF and other lung diseases.
5. Drug developments and clinical trials.
6. Advance imaging methods.
7. Analysis methods development and application of lung images (CT, PET) for the early detection of IPF and other lung diseases. 

Spesific Expertises :
Clinical research, Molecular biology, medical research, genomics, medial image analysis. Human Genetics and Computational Biology. 
Expertise sought: Scientific research, Medical biotechnology, Life sciences, Biotechnology, Medicine. Health, Mathematics. Statistics, 
Roles sought: Project participant, 
Organisation types sought: Research, Education, Industry, Technology transfer, Small or medium-sized enterprise (SME), 
Countries sought: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom, Israel, United States,